Metropolitan Life Insurance Company (MetLife)’s Recursion Pharmaceuticals RXRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,290	Closed	-$72.7K	–	1715
2024 Q1	$72.7K	Sell	7,290 -632	-8%	-$7.04K	﹤0.01%	1215
2023 Q4	$78.1K	Hold	7,922	–	–	﹤0.01%	1213
2023 Q3	$60.6K	Buy	7,922 +373	+5%	+$3.72K	﹤0.01%	1294
2023 Q2	$56.4K	Hold	7,549	–	–	﹤0.01%	1352
2023 Q1	$50.4K	Sell	7,549 -826	-10%	-$6.55K	﹤0.01%	1388
2022 Q4	$64.6K	Hold	8,375	–	–	﹤0.01%	1319
2022 Q3	$89.1K	Hold	8,375	–	–	﹤0.01%	1077
2022 Q2	$68.2K	Buy	8,375 +686	+9%	+$4.59K	﹤0.01%	1305
2022 Q1	$55.1K	Sell	7,689 -22,833	-75%	-$243K	﹤0.01%	1538
2021 Q4	$523K	Buy	30,522 +22,388	+275%	+$421K	0.01%	1389
2021 Q3	$187K	Buy	8,134 +1,467	+22%	+$41.6K	﹤0.01%	2129
2021 Q2	$243K	Buy	+6,667	New	+$197K	﹤0.01%	2005

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RXRX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Recursion Pharmaceuticals (RXRX) in Q2 2024, closing a stake of 7,290 shares — an estimated $72.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RXRX in Q2 2021 and held it in 12 quarters. The position peaked at $523K in Q4 2021. 270 funds tracked by Wall St. Rank hold RXRX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Recursion Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 7,290 Recursion Pharmaceuticals shares in Q2 2024, an estimated $72.7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s Recursion Pharmaceuticals position peaked at $523K in Q4 2021.
270 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.